An HCV NS5A inhibitor
Related Products
Labeled Version(s)
31322Ledipasvir-d6
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ledipasvir

Item No. 18519

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid, methyl ester
CAS Number
1256388-51-8
Synonyms
  • GS-5885
Molecular Formula
C49H54F2N8O6
Formula Weight
889.0
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 20 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH 7.2)(1:2): 0.33 mg/ml
λmax
219, 334 nm
SMILES
FC1(F)C2=C(C=CC(C3=CC(NC([C@H]4N(C([C@H](C(C)C)NC(OC)=O)=O)[C@@H]5CC[C@H]4C5)=N6)=C6C=C3)=C2)C7=CC=C(C8=CN=C([C@@H]9CC%10(CC%10)CN9C([C@H](C(C)C)NC(OC)=O)=O)N8)C=C71
InChi Code
InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14
InChi Key
VRTWBAAJJOHBQU-KMWAZVGDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $54

    Add

    1 mg

    $96

    Add

    5 mg

    $247

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Ledipasvir is an inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A).1,2 It inhibits viral replication in genotype 1a and 1b HCV replicon cells (EC50s = 0.031 and 0.004 nM, respectively). It also inhibits viral replication in genotype 2a, 2b, 3a, 4a, 4d, 5a, 6a, and 6e HCV replicon cells (EC50s = 0.11-530 nM).2 Lepidasvir acts synergistically with IFN-α, ribavirin (Item No. 16757), or GS-9669 and additively with GS-9451, simeprevir (Item No. 22144), daclatasvir (Item No. 23730), or sofosbuvir (Item No. 15402) to inhibit viral replication in genotype 1a HCV replicon cells. Formulations containing ledipasvir have been used in combination therapy for the treatment of chronic HCV infection.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Link, J.O., Taylor, J.G., Xu, L., et al. Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57(5), 2033-2046 (2014).

    2. Cheng, G., Tian, Y., Doehle, B., et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob. Agents Chemother. 60(3), 1847-1853 (2016).